Pharmaceuticals

Global Albumin Excipient Market Revenue and Share Analysis Through 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the albumin excipient market from 2025–2034 with trusted insights from The Business Research Company

What Is The Projected Valuation Of The Albumin Excipient Market In The Period 2029-2034?

The albumin excipient market has experienced robust growth recently. It is forecast to increase from $4.85 billion in 2024 to $5.15 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.1%. This historical expansion can be attributed to the flourishing biopharmaceutical industry, increased acceptance of biologics, a rise in the occurrence of chronic diseases, advancements in clinical research and drug innovation, and a heightened emphasis on drug delivery.

The albumin excipient market is projected to experience substantial expansion over the upcoming years. Its value is set to reach $6.64 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period stems from factors such as ongoing biopharmaceutical expansion, an expanding biologics pipeline, an increasing elderly population, worldwide vaccination efforts, and greater investments in drug development. Key trends emerging within this period encompass biodegradable and biocompatible characteristics, collaborative research and partnerships, adherence to regulatory compliance and quality standards, applications within cell therapy, and the provision of customization and tailored solutions.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10672&type=smp

What Strategic Drivers Are Accelerating The Albumin Excipient Market Expansion?

The increasing occurrence of chronic illnesses is anticipated to fuel the expansion of the albumin excipient market in the future. Chronic diseases are defined as conditions persisting for at least three months, which may worsen over time. Albumin, the most prevalent circulating protein in plasma, functions as a blood volumizer and a versatile carrier for drug targeting. It also enhances the pharmacokinetic profile of peptide or protein-based drugs, crucial in treating various conditions such as cancer and diabetes. For example, in February 2024, the World Health Organization, an agency of the United Nations based in Switzerland, predicted more than 35 million new cancer cases by 2050, which marks a 77% rise from the approximately 20 million cases recorded in 2022. Consequently, the growing incidence of chronic diseases is a key factor propelling the growth of the albumin excipient market.

What Is The Detailed Segment Distribution Of The Albumin Excipient Market?

The albumin excipient market covered in this report is segmented –

1) By Product: Human Serum Albumin, Recombinant Albumin

2) By End-Users: Pharmaceutical And Biotechnology Industry, Research Institutes, Other End Users

Subsegments:

1) By Human Serum Albumin: 5% Human Serum Albumin, 20% Human Serum Albumin

2) By Recombinant Albumin: Recombinant Human Serum Albumin, Recombinant Bovine Serum Albumin

How Are Global Trends Impacting The Development Of The Albumin Excipient Market?

Leading companies in the albumin excipient market are embracing a strategic partnership model to serve critical biotechnology and pharmaceutical industries. These strategic collaborations involve businesses utilizing each other’s strengths and resources to achieve shared benefits and success. For example, in October 2023, ARTES Biotechnology GmbH, a Germany-based biotechnology company, formed a partnership with Basic Pharma, a Netherlands-based pharmaceutical company, to enhance recombinant protein production. Through this alliance, they intend to improve pharmaceutical recombinant protein production by optimizing the supply chain and shortening the time-to-market for new offerings.

Who Are The Major Stakeholders Operating In The Albumin Excipient Market?

Major companies operating in the albumin excipient market include Albumin Therapeutics LLC, Biotest AG, CSL Behring,Grifols S.A., HiMedia Laboratories LLC, InVitria Inc., Medxbio Pte Ltd., Octapharma AG, RayBiotech Inc., SeraCare Life Sciences Inc., Sigma-Aldrich Pty. Ltd., Hualan Biological Engineering Inc., Kedrion Biopharma, LFB USA Inc., Shanghai RAAS Blood Products Co. Ltd., Baxter International Inc., Merck KGaA, Thermo Fisher Scientific Inc., Albumedix A/S, Bio Products Laboratory Ltd., Shire Plc., Ventria Bioscience Inc., Novartis AG, China Biologic Products Holdings Inc., ProMetic Life Sciences Inc., Sanquin, Biopharma, Takeda Pharmaceutical Company Limited, FUJIFILM Irvine Scientific Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/albumin-excipient-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Albumin Excipient Market?

North America was the largest region in the Albumin Excipient market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global albumin excipient market report during the forecast period. The regions covered in the albumin excipient market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=10672&type=smp

Browse Through More Reports Similar to the Global Albumin Excipient Market 2025, By The Business Research Company

Synthetic Biology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/synthetic-biology-global-market-report

Digestive Enzyme Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/digestive-enzyme-global-market-report

Specialty Enzyme Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/specialty-enzyme-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795